Search Results

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the previously announced acquisition of Synteract, a leading full-service CRO focused on the rapidly growing, emerging biopharma segment.

Under Amulet’s ownership, Synteract drove organic growth, integrated several strategic acquisitions, more than doubled EBITDA and expanded its global delivery footprint

Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, has launched the Synteract Rare Disease Institute™, which capitalizes on Synteract’s strengths and skillsets in rare and orphan diseases.

Syneos Health announced on Wednesday that it has agreed to acquire Synteract, a full-service Contract Research Organization (CRO) focused on the biopharmaceutical industry.

Proposed Acquisition Valued at Approximately $15 Million Would Add an Established 50-State Telehealth Business, with over 90,000 clients, Focused on Peptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual Wellness Key Highlights: • Target generated approximately $12.7 million in revenue for the trailing twelve months ended August 2026 (unaudited, as provided by Target management) and is cash-flow positive • Proposed purchase price of approximately $15 million, payable in cash and KALA stock; the cash portion is expected to be funded from existing balance sheet resources • Founded in 2023; LegitScript-certified, NABP-accredited platform serving clients in all 50 states; more than 90,000 clients served since inception • 45-day due diligence period expected to conclude in November 2026; definitive agreements and closing targeted for late 2026 or early 2027